Artificial intelligence is reshaping the way the pharmaceutical world finds and develops new drugs, and Peptris Technologies is right at the center of this shift. The AI-powered drug discovery startup has raised ₹70 crore in a Series A round, co-led by IAN Alpha Fund and Speciale Invest a move that underscores growing investor appetite for deep-tech healthcare solutions in India.
What sets Peptris apart is its focus on going beyond just generating molecules. The company has developed a proprietary AI engine capable of creating novel molecular structures while simultaneously predicting key drug development metrics at an early stage. This allows pharmaceutical companies to make smarter, faster decisions and significantly cut down on the high costs and failure rates that have long plagued drug development pipelines.
Peptris also supports drug companies with patent lifecycle management, adding another layer of value beyond the discovery phase. With several programmes already progressing toward clinical development, the fresh funding will be used to push these forward to clinical readiness and meaningfully grow the company’s overall pipeline over the next two years.
